GGrantIndex
← Search

MONOCLONAL ANTIBODY MUJ591 PATIENTS W/ HORMONE INDEPENDANT PROSTATE CANCER

$0M01FY2001RRNIH

Weill Medical College Of Cornell Univ, New York NY

Investigators

Linked publications, trials & patents

Abstract

Several characteristics of monoclonal antibodies (mAbs) are particularly well suited for the demands of prostate cancer therapy. muJ591 binds specifically with a prostate-related surface antigen. The investigators wish to define the toxicity and preliminary efficacy of mAb muJ591 in patients with hormone-independent prostate cancer.

View original record on NIH RePORTER →
MONOCLONAL ANTIBODY MUJ591 PATIENTS W/ HORMONE INDEPENDANT PROSTATE CANCER · GrantIndex